A deluge of weight-loss drugs is set to transform the global fight against obesity as India prepares to unleash low-cost generic versions of injections like Ozempic after a key patent expired yesterday.
The move would dramatically widen access to treatments that have long been considered a luxury, especially in middle-income countries, where soaring demand has collided with steep prices.
At clinics across Mumbai, doctors say they are already preparing for an influx in new patients.
Photo: AFP
More than 50 people walk into endocrinologist Nadeem Rais’ office every week seeking weight-loss injections.
“We have around 70 to 80 patients on active treatment right now,” he said. “When generics come out and prices drop, that could go up to 200 easily.”
His colleague Sunera Ghai agreed, saying that demand is “very high,” but many “probably aren’t taking it just because it is truly a luxury item at this point”.
The breakthrough comes as patents on semaglutide — the active ingredient in drugs such as Ozempic and Wegovy — expired yesterday in India, the world’s largest supplier of generic medicines.
By the end of the year, core patents on semaglutide would have expired in 10 countries that represent 48 percent of the global obesity burden, a study published earlier this month by researchers said.
These include Brazil, China, South Africa, Turkey and Canada, the study said.
For India’s drug giants, this marks the start of an aggressive new race. At least four major firms have already prepared generic semaglutide injections, regulatory filings and compliance documents viewed by AFP show.
Some, including Zydus Lifesciences, have announced “Day 1” launches, suggesting generic versions might become available as soon as this weekend in India. Research firm Pharmarack estimates the Indian market would soon be flooded with options.
“What we understand is, there will be more than 50 brands that will be launched in the market and there are more than 40 players who will be launching these drugs,” Pharmarack vice president Sheetal Sapale said.
The timing aligns with India’s shifting health landscape.
While India still accounts for one-third of the world’s undernutrition according to the WHO, rising incomes and urban lifestyles have pushed obesity rates sharply upward. Government data released in March last year shows 24 percent of women and 23 percent of men are overweight or obese in India.
“Once a person starts earning money, he becomes more sedentary here,” bariatric surgeon Sanjay Borude said. “While in first-world countries, the more the money, they become more active and devote time for their health, this is reversed in India.”
These flipped economics have worked well for big pharma players like Eli Lilly and Novo Nordisk who have been cashing in on the market.
As of this year, India’s weight-loss drug sales have grown 10-fold in five years to US$153 million and are projected to soar to more than half a billion by 2030.
However, using such drugs can cause side effects including nausea and gastrointestinal issues.
Eli Lilly’s Mounjaro became the country’s top-selling drug by value last year, surpassing even common antibiotics. Still, high prices — often 15,000 to 22,000 rupees (US$160 to US$236) a month — limit access, says Swati Pradhan, who runs a weight-loss clinic in Mumbai. She expects patient numbers to rise once generics push treatment costs closer to 5,000 rupees a month.
The global impact may prove even more profound. India supplies more than half of Africa’s generic medicines, and cheaper semaglutide could become a lifeline for countries where obesity is rising rapidly, but treatment remains unaffordable.
“Lower-cost semaglutide could significantly expand access to effective treatment particularly in middle-income countries where price has been a major barrier,” World Obesity Federation president Simon Barquera said. “Generic products are an important step in breaking the access barrier, now that the scientific one has been overcome.”
Indian firms would be a key driving force, with Dr Reddy’s Laboratories aiming to launch its version of semaglutide in Canada by May.
For patients like 46-year-old Sukant Mangal, who lost nearly 30 pounds (13.6kg) in eight months, wider access could not come soon enough. Many he knows simply abandoned treatment midway when they realized they would have to spend 20,000 rupees a month for seven to eight months.
“Had it been cheaper, [it] would’ve been much easier to have it,” he said.
KINGPIN: Marset allegedly laundered the proceeds of his drug enterprise by purchasing and sponsoring professional soccer teams and even put himself in the starting lineups Notorious Latin American narco trafficker Sebastian Marset, who eluded police for years, was handed over to US authorities after his arrest on Friday in Bolivia. Marset, a Uruguayan national who was on the US most-wanted list, was passed to agents of the US Drug Enforcement Administration at Santa Cruz airport in Bolivia, then put on a US airplane, Bolivian state television showed. “The arrest and deportation were carried out pursuant to a court order issued by the US justice system,” Bolivian Minister of Government Marco Antonio Oviedo told reporters. The alleged kingpin was arrested in an upscale neighborhood of Santa
FAKE NEWS? ‘When the government demands the press become a state mouthpiece under the threat of punishment, something has gone very wrong,’ a civic group said The top US broadcast regulator on Saturday threatened media outlets over negative coverage of the Middle East war, after US President Donald Trump slammed critical headlines from the “Fake News Media.” The US president since his first term has derided mainstream media as “fake news” and has sued major outlets over what he sees as unfair coverage. Brendan Carr, head of the US Federal Communications Commission — which oversees the nation’s radio, television and Internet media — said broadcasters risked losing their licenses over news coverage. “The law is clear. Broadcasters must operate in the public interest, and they will
SCANDAL: Other images discovered earlier show Andrew bent over a female and lying across the laps of a number of women, while Mandelson is pictured in his underpants A photograph of former British prince Andrew and veteran politician Peter Mandelson sitting in bathrobes alongside late sex offender Jeffrey Epstein was unearthed on Friday in previously published documents. The image is believed to be the first known photograph of the two men with Epstein. They are currently engulfed in scandal in the UK over their ties to their mutual friend. The undated photograph, first reported by ITV News, shows King Charles III’s disgraced brother and former British ambassador to the US sitting barefoot outside on a wooden deck. They appear to have mugs with a US flag on them
INFLUTENTIAL THEORIST: Habermas was particularly critical of the ‘limited interest’ shown by German politicians in ‘shaping a politically effective Europe Jurgen Habermas, whose work on communication, rationality and sociology made him one of the world’s most influential philosophers and a key intellectual figure in his native Germany, has died. He was 96. Habermas’ publisher, Suhrkamp, said he died on Saturday in Starnberg, near Munich. Habermas frequently weighed in on political matters over several decades. His extensive writing crossed the boundaries of academic and philosophical disciplines, providing a vision of modern society and social interaction. His best-known works included the two-volume Theory of Communicative Action. Habermas, who was 15 at the time of Nazi Germany’s defeat, later recalled the dawn of
RSS